Emergent Biosolutions, Inc. - Grafik, Fiyat ve Haberler (NYSE:EBS)

Tam grafiği aç

Financials

Genel Bakış Tablolar İstatistikler

Çeyreklik Yıllık

Market Capitalization 428.25 M
Employee 900
Founded 1998
CEO Robert G. Kramer Sr. | Joseph C. Papa
Website www.emergentbiosolutions.com
Headquarter Delaware, United States
FIGI BBG000GW06J7
Industry İlaç Üreticileri - Özel ve Eşdeğer

Toplam gelir

Net kar

Temel hisse başına kazanç (Temel EPS)

Toplam borç

Serbest nakit akışı

Nakit ve eşdeğerleri

Fiyat/kazanç oranı

13.29

Fiyat/satışlar oranı

0.94

Emergent BioSolutions Inc. Common Stock

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.